Skip to main content
AstraZeneca PLC logo

AstraZeneca PLC — Investor Relations & Filings

Ticker · AZN ISIN · GB0009895292 LEI · PY6ZZQWO2IZFZC3IOL08 IL Manufacturing
Open in API
Filings indexed 3,304 across all filing types
Latest filing 2024-01-11 Regulatory Filings
Country GB United Kingdom
Listing IL AZN

About AstraZeneca PLC

https://www.astrazeneca.com/

AstraZeneca PLC is a global, science-led biopharmaceutical company that focuses on the discovery, development, and commercialization of prescription medicines. The company's portfolio is concentrated on several main therapy areas, including Oncology; Cardiovascular, Renal & Metabolism; and Respiratory & Immunology. AstraZeneca is committed to advancing healthcare through a robust research and development pipeline, aiming to deliver innovative medicines that address significant unmet medical needs for millions of patients worldwide. The company leverages scientific innovation to transform the future of healthcare and improve patient outcomes.

Recent filings

Filing Released Lang Actions
SC TO-T/A Filing
Regulatory Filings
2024-01-11 English
TOTAL VOTING RIGHTS
Foreign Filer Report
2024-01-02 English
Total Voting Rights
Declaration of Voting Results & Voting Rights Announcements Classification · 1% confidence The document is identified by the 'RNS Number' header and contains a notification regarding 'Voting rights and capital' as of a specific date (31 December 2023). It explicitly states the total number of voting rights (1,550,162,626) as required by the UK Financial Conduct Authority's Disclosure and Transparency Rule 5.6.1. This type of mandatory, periodic disclosure about the total number of shares with voting rights is a standard regulatory announcement. Since it is a specific regulatory update that doesn't fit the definitions for DVA (Declaration of Voting Results), SHA (Share Issue), or POS (Transaction in Own Shares), and it is a direct regulatory filing announcement format, it best fits the general Regulatory Filings category (RNS), which serves as a fallback for specific regulatory notices not covered elsewhere, or it could be considered a specific type of regulatory update. Given the content is purely about the total voting rights denominator, RNS is the most appropriate general regulatory classification, although DVA is related to voting, DVA is for *results* of a vote, not the total rights count itself. RNS is the best fit for this specific regulatory disclosure format.
2024-01-02 English
ASTRAZENECA ACQUIRES GRACELL
Foreign Filer Report
2023-12-27 English
AstraZeneca acquires Gracell
M&A Activity Classification · 1% confidence The document is an official announcement dated December 27, 2023, from AstraZeneca PLC, disseminated via RNS (Regulatory News Service). The content details a definitive agreement to acquire Gracell Biotechnologies Inc., including financial considerations, transaction structure (merger, contingent value rights), and expected closing timeline. This type of announcement, concerning a major corporate transaction (M&A), is typically classified as a significant regulatory disclosure. While it relates to a transaction (TAR), the format and dissemination method (RNS Number: 8453X) strongly suggest it is a broad regulatory filing. Since M&A (TAR) is a specific category, and this is a detailed announcement of the transaction terms, TAR is the most appropriate primary classification. However, the document explicitly uses the RNS header and structure, and the content is a major corporate event announcement, which often falls under general regulatory disclosure if TAR is not strictly defined as the announcement itself. Given the detailed nature (16k characters) and the explicit RNS header, it is a significant regulatory filing. Since the core event is a takeover/merger proposal, TAR (M&A Activity) is the most specific fit for the *content*, but RNS is the format. Given the options, M&A Activity (TAR) describes the substance best, but since it is a formal regulatory announcement, RNS is also plausible. Let's re-evaluate based on definitions. TAR is for 'merger proposals or takeover bids'. This is a definitive agreement for an acquisition, which fits TAR perfectly. It is not just a short announcement of a report (RPA/RNS fallback). Therefore, TAR is the best fit.
2023-12-27 English
SC TO-T Filing
Regulatory Filings
2023-12-27 English

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.